Botulinum toxin antibodies
In October 2017, Nanotherapeutics completed a phase I trial which assessed the safety and pharmacokinetics of NTM 1634 in healthy subjects (NTM-1634-001; 272201600009C-2-0-1; NCT03046550). The double blind, randomised, dose escalation trial was initiated in March 2017, and enrolled 24 healthy volunteers in the US  . In September 2017, Xoma announced that it has earned a $US3 million milestone payment related to this clinical advancement of NTM 1634. The company received an initial cash payment of $US250,000 related to the milestone. The remaining amounts of the milestone payment will be received in monthly payments over the next eleven months  .
In September 2011, Nanotherapeutics was awarded a contract of $US2 049 872 (Contract No. 272201600009C-2-0-1) to support the advanced development of promising biodefense therapeutic candidates/products with broad spectrum activity. The research and development activities supported will allow candidate therapeutic countermeasures to progress through the product development pipeline, and includes preclinical/non-clinical and clinical IND development activities.
In October 2011, XOMA was awarded a contract of up to $US28 million over 5 years by the NIAID, to develop its monoclonal antibody-based antitoxins for use in the treatment of botulism poisoning. XOMA planned to use the funding primarily to expand into the development of antibody antitoxins for botulinum toxins C and D   .
XOMA received a grant of $US977 917 in November 2010, under the Patient Protection and Affordable Care Act of 2010 (PPACA) to fund four of the company's therapeutic antibody projects, including the development of antibotulinum toxin antibodies  .
In September 2008, XOMA was awarded a $US65 million multiple-year contract (Contract No. HHSN272200800028C) from the NIAID to support the ongoing development of antibotulism antibodies towards clinical trials  . In 2005 and 2006, XOMA was awarded contracts by NIAID worth over $US31 million, for the development of antibodies against botulinum toxin A, which have since entered clinical trials    .
Influenza virus antibodies
In September 2009, XOMA expanded its biodefence programmes to include the development of a novel antibody, known as F10, as a potential therapy for the treatment of both seasonal and pandemic virus infections, particularly for patients who are immunocompromised or unvaccinated, or those infected with drug-resistant viral strains. The F10 antibody was initially developed at Dana-Farber Cancer Institute and Harvard Medical School; studies conducted there showed the F10 antibody to neutralise group 1 influenza A viruses, including the H1N1 (swine flu) and H5N1 (bird flu) strains. The F10 antibody binds to a region on which is present across group 1 influenza A viruses. Because the region undergoes less structural change due to mutation or reassortment than vaccine targets, an antibody that binds to it could potentially be used to treat multiple influenza viral strains and be useful over multiple influenza seasons. In early studies, the F10 antibody appears to stop the spread of the influenza virus by preventing replication after viral particles enter cells  .
By January 2010, the company had obtained $US3.9 million in new government contracts for the development of antibodies to the H1N1 and H5N1 influenza strains and SARS viruses  .